Trial reportNature communications2022
Serum metabolic traits reveal therapeutic toxicities and responses of neoadjuvant chemoradiotherapy in patients with rectal cancer.
Trial report in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- A systematic review of omics discovery studies to identify pertinent metabolic pathways for locally advanced rectal cancer in response to neoadjuvant chemoradiotherapy.Metabolomics : Official journal of the Metabolomic Society · 2025Pooled it
- Artificial intelligence for evaluation of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer.PLOS digital health · 2026Article
- Article
- KRASCellular & molecular biology letters · 2026Article
- Oncological Outcomes and Risk Factors for Local Recurrence and Distant Metastasis After Upfront Surgery in cT3 Rectal Cancer With an Uninvolved Circumferential Resection Margin on Magnetic Resonance Imaging.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Serum Metabolomic Profiles Predict Sensitivity and Toxicity to Platinum- Fluorouracil Chemotherapy in a Gastric Cancer Xenograft Model.Combinatorial chemistry & high throughput screening · 2026Article
- Magnetic Resonance Imaging Features as Predictors of Response and Prognosis Following Neoadjuvant Therapy in Rectal Cancer: A Retrospective Cohort Study.Clinical Medicine Insights. Oncology · 2026Article
- Bioactive Constituents of Ginseng in Cancer Therapy: Molecular Mechanisms, Translational Potential, and Advanced Delivery Strategies.International journal of biological sciences · 2026Review
- Predictive value of a nomogram model for treatment response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.World journal of gastrointestinal oncology · 2025Article
- Gut-Microbiome Signatures Predicting Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: A Systematic Review.Metabolites · 2025Review
- Gut-derivediMeta · 2025Article
- S-adenosylmethionine metabolism shapes CD8Cancer & metabolism · 2025Article
- Microbiota alterations leading to amino acid deficiency contribute to depression in children and adolescents.Microbiome · 2025Article
- Serum metabolomics to identify molecular subtypes and predict XELOX efficacy in colorectal cancer.Scientific reports · 2025Article
- Comprehensive MALDI mass spectrometry imaging of tumor regions post-neoadjuvant therapy.Analytical and bioanalytical chemistry · 2025Article
- Multiomic traits reveal that critical irinotecan-related core regulator FSTL3 promotes CRC progression and affects ferroptosis.Cancer cell international · 2025Article
- Association of metabolic dysregulation with treatment response in rectal cancer patients undergoing chemoradiotherapy.BMC medical genomics · 2025Article
- Serum metabolomic profiling for predicting therapeutic response and toxicity in breast cancer neoadjuvant chemotherapy: a retrospective longitudinal study.Breast cancer research : BCR · 2025Article
- Higher BMI reduces mortality in elderly and Stage III colorectal cancer patients: insights from a multicenter cohort study.Frontiers in nutrition · 2025Article
- Camptothecin-PHA nanoparticles attenuate drug-induced gut microbiome dysbiosis and metabolic toxicity.Frontiers in microbiology · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant chemoradiotherapy (nCRT) has become the standard treatment for patients with locally advanced rectal cancer (LARC). Therapeutic efficacy of nCRT is significantly affected by treatment-induced diarrhea and hematologic toxicities. Metabolic alternations in cancer therapy are key determinants to therapeutic toxicities and responses, but exploration in large-scale clinical studies remains limited. Here, we analyze 743 serum samples from 165 LARC patients recruited in a phase III clinical study using untargeted metabolomics and identify responsive metabolic traits over the course of nCRT. Pre-therapeutic serum metabolites successfully predict the chances of diarrhea and hematologic toxicities during nCRT. Particularly, levels of acyl carnitines are linked to sex disparity in nCRT-induced diarrhea. Finally, we show that differences in phenylalanine metabolism and essential amino acid metabolism may underlie distinct therapeutic responses of nCRT. This study illustrates the metabolic dynamics over the course of nCRT and provides potential to guide personalized nCRT treatment using responsive metabolic traits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.